Fort Lauderdale, Florida 33308

  • Multiple Sclerosis

Purpose:

The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to Gilenya before (up to 8 weeks before last menstrual period) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.


Criteria:

Inclusion Criteria: - Pregnancy and reported confirmed or suspected maternal exposure to Gilenya any time during pregnancy or shortly before pregnancy (up to 8 weeks before LMP). - Informed consent Exclusion Criteria: - There are no specific exclusion criteria for this registry. Other protocol-defined inclusion/exclusion criteria may apply


NCT ID:

NCT01285479


Primary Contact:

Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals

Novartis Pharmaceuticals
Phone: 1-888-669-6682


Backup Contact:

Novartis Pharmaceuticals
Phone: +41613241111


Location Contact:

Fort Lauderdale, Florida 33308
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 25, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.